Literature DB >> 33801234

Type I and II Interferons in the Anti-Tumor Immune Response.

Sarah E Fenton1,2, Diana Saleiro1,2, Leonidas C Platanias1,2,3.   

Abstract

The interferons (IFNs) are essential components of the immune response against infections and malignancies. IFNs are potent promoters of the anti-tumor response, but there is also evidence that feedback mechanisms regulated by IFNs negatively control immune responses to avoid hyper-activation and limit inflammation. This balance of responses plays an important role in cancer surveillance, immunoediting and response to anticancer therapeutic approaches. Here we review the roles of both type I and type II IFNs on the control of the immune response against malignancies in the context of effects on both malignant cells and cells of the immune system in the tumor microenvironment.

Entities:  

Keywords:  T cell; cancer; cancer immunoediting; dendritic cell; interferons; macrophage

Year:  2021        PMID: 33801234      PMCID: PMC7957896          DOI: 10.3390/cancers13051037

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  199 in total

1.  Type I IFN contributes to NK cell homeostasis, activation, and antitumor function.

Authors:  Jeremy B Swann; Yoshihiro Hayakawa; Nadeen Zerafa; Kathleen C F Sheehan; Bernadette Scott; Robert D Schreiber; Paul Hertzog; Mark J Smyth
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

Review 2.  Innate immune sensing and signaling of cytosolic nucleic acids.

Authors:  Jiaxi Wu; Zhijian J Chen
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

3.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

Review 4.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

5.  Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression.

Authors:  Giulia Escobar; Davide Moi; Anna Ranghetti; Pinar Ozkal-Baydin; Mario Leonardo Squadrito; Anna Kajaste-Rudnitski; Attilio Bondanza; Bernhard Gentner; Michele De Palma; Roberta Mazzieri; Luigi Naldini
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

6.  Delayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN-β.

Authors:  Lisa Andzinski; Ching-Fang Wu; Stefan Lienenklaus; Andrea Kröger; Siegfried Weiss; Jadwiga Jablonska
Journal:  Int J Cancer       Date:  2014-05-16       Impact factor: 7.396

Review 7.  CD8(+) T cells: foot soldiers of the immune system.

Authors:  Nu Zhang; Michael J Bevan
Journal:  Immunity       Date:  2011-08-26       Impact factor: 31.745

8.  Differences in the tumor microenvironment between African-American and European-American breast cancer patients.

Authors:  Damali N Martin; Brenda J Boersma; Ming Yi; Mark Reimers; Tiffany M Howe; Harry G Yfantis; Yien Che Tsai; Erica H Williams; Dong H Lee; Robert M Stephens; Allan M Weissman; Stefan Ambs
Journal:  PLoS One       Date:  2009-02-19       Impact factor: 3.240

9.  Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.

Authors:  Diana Rose E Ranoa; Akash D Parekh; Sean P Pitroda; Xiaona Huang; Thomas Darga; Anthony C Wong; Lei Huang; Jorge Andrade; Jonathan P Staley; Takashi Satoh; Shizuo Akira; Ralph R Weichselbaum; Nikolai N Khodarev
Journal:  Oncotarget       Date:  2016-05-03

10.  Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.

Authors:  Elisabeth Müller; Martin Speth; Panagiotis F Christopoulos; Anna Lunde; Ajna Avdagic; Inger Øynebråten; Alexandre Corthay
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

View more
  12 in total

Review 1.  What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?

Authors:  Alejandro Garcia-Alvarez; Jorge Hernando Cubero; Jaume Capdevila
Journal:  Curr Oncol Rep       Date:  2022-02-16       Impact factor: 5.075

2.  Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Roni Shouval; Ana Alarcon Tomas; Joshua A Fein; Jessica R Flynn; Ettai Markovits; Shimrit Mayer; Aishat Olaide Afuye; Anna Alperovich; Theodora Anagnostou; Michal J Besser; Connie Lee Batlevi; Parastoo B Dahi; Sean M Devlin; Warren B Fingrut; Sergio A Giralt; Richard J Lin; Gal Markel; Gilles Salles; Craig S Sauter; Michael Scordo; Gunjan L Shah; Nishi Shah; Ruth Scherz-Shouval; Marcel van den Brink; Miguel-Angel Perales; Maria Lia Palomba
Journal:  J Clin Oncol       Date:  2021-12-03       Impact factor: 44.544

3.  [ELF4 promotes proliferation and inhibits apoptosis of human insulinoma cells by activating Akt signaling].

Authors:  G Wei; L Wang; X Wan; Y Tan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-08-31

Review 4.  HIF1, HSF1, and NRF2: Oxidant-Responsive Trio Raising Cellular Defenses and Engaging Immune System.

Authors:  Anna M Cyran; Anatoly Zhitkovich
Journal:  Chem Res Toxicol       Date:  2022-08-10       Impact factor: 3.973

5.  Oncolytic Vaccinia Virus Harboring Aphrocallistes vastus Lectin Inhibits the Growth of Hepatocellular Carcinoma Cells.

Authors:  Riqing Jiang; Yufeng Qiu; Xiaomei Zhang; Ningning Zhou; Xiaoyuan Jia; Kan Chen; Yanrong Zhou; Ting Ye; Gongchu Li
Journal:  Mar Drugs       Date:  2022-06-04       Impact factor: 6.085

6.  High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients.

Authors:  Yun-Cian Huang; Jau-Ling Huang; Lu-Chia Tseng; Ping-Hung Yu; Si-Yun Chen; Chang-Shen Lin
Journal:  J Pers Med       Date:  2022-01-21

Review 7.  Hypoxia promotes the tolerogenic phenotype of plasmacytoid dendritic cells in head and neck squamous cell carcinoma.

Authors:  Cui Fan; Jichang Wu; Yilin Shen; Haixia Hu; Quan Wang; Yufeng Mao; Bin Ye; Mingliang Xiang
Journal:  Cancer Med       Date:  2021-12-28       Impact factor: 4.452

8.  Regulation of IFNα-induced expression of the short ACE2 isoform by ULK1.

Authors:  Ricardo E Perez; Diana Saleiro; Liliana Ilut; Gary E Schiltz; Frank Eckerdt; Eleanor N Fish; Leonidas C Platanias
Journal:  Mol Immunol       Date:  2022-04-27       Impact factor: 4.174

9.  Prometastatic Effect of ATX Derived from Alveolar Type II Pneumocytes and B16-F10 Melanoma Cells.

Authors:  Mélanie A Dacheux; Sue Chin Lee; Yoojin Shin; Derek D Norman; Kuan-Hung Lin; Shuyu E; Junming Yue; Zoltán Benyó; Gábor J Tigyi
Journal:  Cancers (Basel)       Date:  2022-03-21       Impact factor: 6.639

Review 10.  Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC.

Authors:  Carlotta Cattolico; Peter Bailey; Simon T Barry
Journal:  Front Cell Dev Biol       Date:  2022-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.